IPS Biopharma AG

Immunophotonics is a private biotechnology company that is developing a proprietary carbohydrate polymer (IP-001) for use after a common tumor ablation procedure to induce a systemic anti-tumor immune response. Immunophotonics has subsidiaries in Bern, Switzerland and Tianjin, China. We are a multidisciplinary team of highly experienced individuals committed to pioneering the future of cancer immunotherapy.

Immunophotonics has developed a well thought-out and sophisticated offensive patent strategy, taking a multi-faceted, multi-layered approach to protecting not just the novel composition itself and the application of that novel composition as a method of treatment, but also the chemical space surrounding the novel composition. Our composition of matter patent has been issued in several countries with coverage until 2033. In addition to IP-001, our core platform technology and intellectual property will allow the continued development of additional novel carbohydrate polymers for use in the cancer immunotherapy space.